These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 19010207)

  • 1. Preemptive therapy for cytomegalovirus disease in allogeneic stem cell transplant recipients.
    de la Cruz-Vicente F; Cerezuela Martinez P; Gil-Espárraga E; Martin Aguilera C; Aguilar Guisado M; Parody Ruiz-Berdejo R; Cisneros Herreros JM; Urbano-Ispizua A; Espigado Tocino I
    Transplant Proc; 2008 Nov; 40(9):3102-3. PubMed ID: 19010207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients.
    Len O; Gavaldà J; Aguado JM; Borrell N; Cervera C; Cisneros JM; Cuervas-Mons V; Gurguí M; Martin-Dávila P; Montejo M; Muñoz P; Bou G; Carratalà J; Torre-Cisneros J; Pahissa A;
    Clin Infect Dis; 2008 Jan; 46(1):20-7. PubMed ID: 18171208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients.
    van der Heiden PL; Kalpoe JS; Barge RM; Willemze R; Kroes AC; Schippers EF
    Bone Marrow Transplant; 2006 Apr; 37(7):693-8. PubMed ID: 16501590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation.
    Ayala E; Greene J; Sandin R; Perkins J; Field T; Tate C; Fields KK; Goldstein S
    Bone Marrow Transplant; 2006 May; 37(9):851-6. PubMed ID: 16532016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can low-dose preemptive valganciclovir replace standard intravenous ganciclovir treatment in recipients of allogeneic stem cell transplantation?
    Kaynar L; Metan G; Gökahmetoğlu S; Kurnaz F; Mumcuoğlu H; Öztürk A; Şıvgın S; Pala C; Yıldız O; Eser B; Ünal A; Çetin M
    J Chemother; 2013 Oct; 25(5):286-91. PubMed ID: 24070136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence, risk factors, and outcome of cytomegalovirus infection and disease in patients receiving prophylaxis with oral valganciclovir or intravenous ganciclovir after umbilical cord blood transplantation.
    Montesinos P; Sanz J; Cantero S; Lorenzo I; Martín G; Saavedra S; Palau J; Romero M; Montava A; Senent L; Martínez J; Jarque I; Salavert M; Córdoba J; Gómez L; Weiss S; Moscardó F; de la Rubia J; Larrea L; Sanz MA; Sanz GF
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):730-40. PubMed ID: 19450758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
    Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Impact of initial cytomegalovirus viral load on efficacy of preemptive therapy with ganciclovir in allogeneic stem cell transplant recipients].
    Torre-Cisneros J; Caston-Osorio JJ; Martín C; Rivero A; Doblas A; Rojas R; Gómez P; Martínez F; Torres A
    Enferm Infecc Microbiol Clin; 2010 Jan; 28(1):6-12. PubMed ID: 19409666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation.
    Busca A; de Fabritiis P; Ghisetti V; Allice T; Mirabile M; Gentile G; Locatelli F; Falda M
    Transpl Infect Dis; 2007 Jun; 9(2):102-7. PubMed ID: 17461994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
    Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A
    Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of valgancyclovir as preemptive therapy for the prevention of cytomegalovirus disease in solid organ transplant recipients.
    Díaz-Pedroche C; Lumbreras C; Del Valle P; San Juan R; Hernando S; Folgueira D; Andrés A; Delgado J; Meneu JC; Morales JM; Moreno E; Aguado JM
    Transplant Proc; 2005 Nov; 37(9):3766-7. PubMed ID: 16386532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of low-dose ganciclovir preemptive therapy in allogeneic haematopoietic stem cell transplant recipients compared with conventional-dose ganciclovir: a prospective observational study.
    Park SY; Lee SO; Choi SH; Kim YS; Woo JH; Baek S; Sung H; Kim MN; Kim DY; Lee JH; Lee JH; Lee KH; Kim SH
    J Antimicrob Chemother; 2012 Jun; 67(6):1486-92. PubMed ID: 22354954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation.
    Kalpoe JS; Schippers EF; Eling Y; Sijpkens YW; de Fijter JW; Kroes AC
    Antivir Ther; 2005; 10(1):119-23. PubMed ID: 15751769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose valganciclovir as preemptive therapy for cytomegalovirus infection occurring in allogeneic stem cell transplant recipients.
    Palladino M; Laurenti L; Chiusolo P; Piccioni P; Innocenti I; Tarnani M; Sorà F; Sica S; Leone G
    Acta Haematol; 2010; 123(4):230-4. PubMed ID: 20424437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of preemptive anti-CMV therapy with valganciclovir after kidney transplantation.
    Lopau K; Greser A; Wanner C
    Clin Transplant; 2007; 21(1):80-5. PubMed ID: 17302595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir.
    Mattes FM; Hainsworth EG; Hassan-Walker AF; Burroughs AK; Sweny P; Griffiths PD; Emery VC
    J Infect Dis; 2005 Jan; 191(1):89-92. PubMed ID: 15593008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease.
    Singh N; Wannstedt C; Keyes L; Gayowski T; Wagener MM; Cacciarelli TV
    Transplantation; 2005 Jan; 79(1):85-90. PubMed ID: 15714174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literature.
    Chawla JS; Ghobadi A; Mosley J; Verkruyse L; Trinkaus K; Abboud CN; Cashen AF; Stockerl-Goldstein KE; Uy GL; Westervelt P; DiPersio JF; Vij R
    Transpl Infect Dis; 2012 Jun; 14(3):259-67. PubMed ID: 22093134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients.
    Park JM; Lake KD; Arenas JD; Fontana RJ
    Liver Transpl; 2006 Jan; 12(1):112-6. PubMed ID: 16382458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytomegalovirus prophylaxis using oral ganciclovir or valganciclovir in kidney and pancreas-kidney transplantation under antibody preconditioning.
    Keven K; Basu A; Tan HP; Thai N; Khan A; Marcos A; Starzl TE; Shapiro R
    Transplant Proc; 2004 Dec; 36(10):3107-12. PubMed ID: 15686707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.